The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for optimizing the review and approval procedures of supplementary drug applications, a program introduced in February this year. The initiative aims to enhance the efficiency of drug application reviews and has designated Beijing, Tianjin, Hebei province, Shanghai, Jiangsu province, Zhejiang province, Shandong province, Guangdong province, Chongqing province, and Sichuan province as pilot regions.
Beijing and Shanghai Lead the Way in Streamlining Drug Reviews
In line with the NMPA’s initiative, the Beijing Municipal Medical Insurance Bureau announced a set of Measures “to Support the High-Quality Development of Innovative Medicine in Beijing” in April this year. These measures include a significant reduction in the review timeline for drug supplementary applications from 200 days to 60 days. This move is part of a broader effort to support the high-quality development of innovative medicines in the capital.
Shanghai’s Measures to Boost Biopharmaceutical Industry
The Shanghai municipal government also took steps to bolster the biopharmaceutical industry in the region in August, introducing a set of measures that include reducing the time limit for supplemental drug application reviews to 60 working days. These measures are designed to accelerate the drug approval process, thereby fostering a more conducive environment for the biopharmaceutical industry in Shanghai.-Fineline Info & Tech
Leave a Reply